King's College London

kcl.ac.uk

Total trials

498

Active

106

Phase 3

10

Total enrollment

11,343,061

Read this sponsor's pipeline like an analyst.

Generate a written report: strategic focus, priority programs, pipeline shape, recent terminations and momentum, and the trials worth watching in the next 12 months.

~15-30 sec · cached for 24h

Pipeline matrix

Showing 13 of 13 active programs · click any cell for trials

InterventionEarly Phase 1Phase 1Phase 2Phase 3Phase 4N/ATotal
Metformin1
Ursodeoxycholic Acid1
Encapsulated FMT1
Empagliflozin 10mg OD1
Mirtazapine1
Levetiracetam2
delta-9-tetrahydrocannabinol1
Blood Product1
Psilocybin1
Diroximel fumarate1
Methotrexate1
Dupilumab1
Minocycline 200mg1

Next readouts

  • 2024-12-31
  • 2025-12-01
  • 2026-02
  • 2026-04
  • 2026-05
  • 2026-12
  • 2027-01-20
  • 2027-09-01
  • 2028-01-31
  • 2029-10

Top conditions

  • Anxiety19
  • Depression17
  • Healthy16
  • Psychosis13
  • Schizophrenia10
  • Major Depressive Disorder9
  • Autism Spectrum Disorder8
  • Anorexia Nervosa8

Frequently asked questions about King's College London

How many clinical trials does King's College London have on ClinicalTrials.gov?
King's College London is listed as the lead sponsor on 498 clinical trials in ClinicalTrials.gov, 106 of which are currently active (recruiting, enrolling, or ongoing).
How many of King's College London's trials are in Phase 3?
10 of King's College London's trials are in Phase 3, spread across 13 active drug programs.
What therapeutic areas does King's College London focus on?
King's College London's most-studied conditions on ClinicalTrials.gov are Anxiety, Depression, Healthy, Psychosis, Schizophrenia.
When are King's College London's next clinical trial readouts?
King's College London has 10 upcoming primary-completion readouts tracked here; the soonest is “Ursodeoxycholic Acid vs Metformin in Gestational Diabetes Mellitus”, expected around 2024-12-31.